A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

This study is tracking patients with stage III non-small cell lung cancer whose tumors have specific genetic mutations (called driver mutations). The goal is to understand how traces of leftover cancer DNA in the blood — called circulating tumor DNA — can predict whether the cancer comes back after treatment. **You may be eligible if...** - You have stage III non-small cell lung cancer confirmed by imaging and biopsy - You are 18 or older and in reasonably good physical health (ECOG 0–1) - Your tumor has tested positive for at least one driver gene mutation (such as EGFR, ALK, ROS1, KRAS, or others) - You are planning to have surgery or combined chemotherapy and radiation - You are willing to provide blood samples periodically **You may NOT be eligible if...** - You have had another cancer in the past 5 years - You have other serious illnesses that could affect your ability to participate or your short-term survival Talk to your doctor to see if this trial is right for you.